Informing the Pharmaceutical Drug Development and Commercialization Industry.
Cary, N.C. – March 19, 2014 – Industry Standard Research (ISR) is announcing the launch of its 6th annual CRO Quality Benchmarking series with today’s release of its “CRO Quality Benchmarking – Phase II/III Service Providers (2014)” report. This report provides a Consumer Reports-style analysis of CRO quality with respondents giving quality ratings for 474 service encounters across 29 Phase II/III CROs.
“The data from this year’s study show strong loyalty among sponsors toward their mid-size CROs, and at the top of this list is DCRI,” explained Kevin Olson, CEO of Industry Standard Research. “The Overall Satisfaction, Willingness to Recommend, and Likelihood to Use Againscores for the mid-size CROs, namely DCRI, Chiltern, Medpace, Worldwide Clinical Trials, and Charles River, are higher than those for many of the larger CROs. What’s more, when you combine the 2014 data with those from our previous two studies, the three-year rolling averages for loyalty are starting to favor the mid-size CROs as well.”
In the research, each CRO is evaluated across 25 service quality attributes that are broken down into three categories:
1. Staff Characteristics
2. Operational Excellence
3. Organizational and Finance Characteristics
Results show that Charles River, Chiltern, DCRI, and Medpace are among the leaders for two of these three categories while SGS Life Sciences is among the leaders in all three categories.
“Independently collected performance data like these are critical to our industry,” Olson continued. “Having this information at their fingertips makes service buyers more effective by allowing them to tap into experience beyond their own organizations’ walls. Additionally, the service provider community has come to rely on our Quality Benchmarking studies as tools to understand their competitive delivery positions.”
Also included in the CRO Quality Benchmarking – Phase II/III Service Providers report are clinical outsourcing trends, methods for service provider differentiation, and an analysis of the top drivers of CRO selection.
CROs included in this analysis: Accenture, Aptiv Solutions, BioClinica, Charles River, Chiltern, Clinical Research Services (CRS), Clinipace, Clinsys, Cognizant, Covance, DCRI, Encorium, Eurofins, Frontage, HungaroTrial, ICON, INC Research, inVentiv Health Clinical, Medpace, PAREXEL, PPD, PRA, Premier Research, Quintiles, Rho, SGS Life Sciences, Tata, Theorem, and Worldwide Clinical Trials.
For more information on ISR’s “CRO Quality Benchmarking – Phase II/III Service Providers (2014)” report, please visit ISR’s report page at https://isrreports.com/product/cro-quality-benchmarking-phase-iiiii-service-providers-2014/.
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit the company’s Web site atwww.ISRreports.com, email info@ISRreports.com, or follow us on Twitter @ISRreports.
